Building clinical trials capacity for tuberculosis drugs in high-burden countries
2007

Building Clinical Trials Capacity for Tuberculosis Drugs

Sample size: 25000 publication Evidence: high

Author Information

Author(s): Neil Schluger, Unni Karunakara, Christian Lienhardt, Thomas Nyirenda, Richard Chaisson

Hypothesis

There is an urgent need for more effective treatments for tuberculosis, especially in high-burden countries.

Conclusion

An urgent and massive expansion of clinical trials capacity is needed to accelerate the development and evaluation of new TB drugs.

Supporting Evidence

  • The long duration of TB therapy and high prevalence of drug-resistant TB highlight the need for better treatments.
  • Funding of US$300–US$500 million annually is needed to conduct a comprehensive clinical trials agenda.
  • Over 25,000 patients were enrolled in trials by the British Medical Research Council to evaluate TB treatments.

Takeaway

We need to do more tests to find better medicines for tuberculosis, especially in places where many people are sick.

Methodology

The article discusses the need for clinical trials and the infrastructure required to conduct them effectively in high-burden countries.

Limitations

Current funding for TB drug development and clinical trials is very low, and there is insufficient infrastructure in many high-burden countries.

Participant Demographics

The study emphasizes the need for trials in special populations, including people with HIV, children, and patients with extrapulmonary TB.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040302

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication